Frequently Asked Questions
The market is segmented based on Global Non-Small Cell Lung Cancer Market, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastina Tumours, Mesothelioma and Chest Wall Tumours), Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multi-kinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others) – Industry Trends and Forecast to 2030.
.
The Global Non Small Cell Lung Cancer Market size was valued at USD 26948.36 USD Million in 2022.
The Global Non Small Cell Lung Cancer Market is projected to grow at a CAGR of 13.9% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
